Innovations Through Mergers and Acquisitions in the Pharmaceutical Sector PDF Download

Author: Abdul Wajid
Publisher:
ISBN:
Category :
Languages : en
Pages : 0

View

Book Description

Author: Management Association, Information Resources
Publisher: IGI Global
ISBN: 1668438860
Category : Business & Economics
Languages : en
Pages : 1235

View

Book Description
The Sustainable Development Goals are an ongoing focus around the world as the needs of people and society continue to evolve at a rapid pace. The need for a more sustainable future has never been more pressing as issues such as climate change, natural disasters, and overpopulation present unique difficulties for the decision makers of the world. In order for them to make the best decisions regarding current priorities and strategies, up-to-date and detailed research regarding where we currently are as a society, where we want to be, and the many challenges that stand in the way is crucial. The Research Anthology on Measuring and Achieving Sustainable Development Goals is a comprehensive assessment of the current innovative research and discussions on the challenges to achieving the UN’s Sustainable Development Goals and the measures that have already been put in place to achieve them. Covering topics such as green consumer behavior and peace promotion, this book is vital for academicians, scientists, researchers, students, postdoctoral students, specialists, practitioners, businesses, governmental institutions, decision makers, environmentalists, and policymakers.

Author: Timothy Pang
Publisher:
ISBN: 9789276085584
Category :
Languages : en
Pages :

View

Book Description

Author: Geetika Jain
Publisher: Business Science Reference
ISBN: 9781522599401
Category : Sustainable development
Languages : en
Pages : 0

View

Book Description
"This book explores the issue of sustainable business development goals in emerging economies. It also examines a wide range of techniques and technology adaption methods for adopting and achieving a sustainable competitive advantage"--

Author: Mark Thomas
Publisher: Taylor & Francis
ISBN: 1040008828
Category : Business & Economics
Languages : en
Pages : 211

View

Book Description
Covid-19 has brought so much uncertainty, but one certainty is that the vaccine race will generate winners and losers in the pharmaceutical and biotechnology industries. This will have a major impact on merger and acquisition activity. While the plethora of merger and acquisition deals are abundantly reported by the news media, there is a clear lack of in-depth analysis on the multiple rationales and various challenges in the life sciences industry. By offering contributions from a variety of experts in the biotechnology and pharmaceutical industries, as well as experts on mergers and acquisitions, this edited collection will draw upon the knowledge of a variety of different actors within the fields of pharma and biotech. This book offers a timely exploration of the complexities of mergers and acquisitions in the pharmaceutical and biotechnology industries while seeking to bridge the gap between theory and practice. It presents a critical analysis of the rationale for acquisitions and studies the challenges of ensuring a successful deal. In the light of the Covid-19 pandemic, it will also explore the impact this may have on the industry, which may further stimulate merger and acquisition activity. It will be of interest to researchers, academics, policymakers, and students in the fields of strategy, management, governance, and the biotechnology and pharmaceutical industries.

Author: Julian Kahl
Publisher:
ISBN: 9783830080480
Category : Consolidation and merger of corporations
Languages : en
Pages : 124

View

Book Description

Author: R. D. Neirinckx
Publisher: Rudi Neirinckx
ISBN: 186067464X
Category : Commerce
Languages : en
Pages : 201

View

Book Description

Author: Martin Wenderoth
Publisher: GRIN Verlag
ISBN: 3640267036
Category : Business & Economics
Languages : en
Pages : 19

View

Book Description
Essay from the year 2008 in the subject Business economics - Offline Marketing and Online Marketing, grade: (4) good, Eötvös Loránd Tudományegytem (International PhD Program), course: Business Economics, language: English, abstract: Within the ongoing globalisation process, many national markets and industrial branches are in different phases of the transition from local to global economic structures (Bryan, L.; Fraser, J.; Oppenheim, J. Rall, W., 2000, pp. 71-95). As a result of this development organisations in the different industries are increasingly concentrating (Brühl, V., 2003, pp. 274-278). Among other industries, also the pharmaceutical industry is highly influenced by the above mentioned trend, reflected by the increasing number of mergers and acquisitions (M&A’s) in the pharmaceutical industry, which is illustrated in the following figure. Figure 1: The present assignment is going to evaluate the reasons and consequences of M&A’s within the pharmaceutical industry by using the sanofi-aventis merger as an example. First of all, the recent history of sanofi-aventis is briefly described. The third part will describe the reasons and consequences of mergers and acquisitions in the pharmaceutical industry by describing the challenges the pharmaceutical branch is confronted with and the respective motives of and results from M&A activities. Finally, the major findings are summarised and conclusions will be derived. 2. History of sanofi-aventis Following the company homepage of sanofi-aventis (20071), the year 1999 has been very im-portant because of two reasons. First of all, Sanofi took over the Synthelabo Holding GmbH and changed its company name to Sanofi-Synthelabo. Furthermore, Hoechst merged with Rhône-Poulenc, a French chemical and pharmaceutical organisation in order to form the new company Aventis, with its legal seat in Strassbourgh (...)

Author: Joanna Shepherd
Publisher:
ISBN:
Category :
Languages : en
Pages : 26

View

Book Description
Recent changes in the pharmaceutical industry have spurred an unprecedented wave of mergers and acquisitions. Some researchers and agencies have questioned whether pharmaceutical consolidation could impede drug innovation. However, as I explain in this Article, these concerns are largely based on an outdated understanding of the drug innovation ecosystem. Whereas a few decades ago almost all drug discovery took place inside traditional pharmaceutical companies, today most drug innovation is externally-sourced from biotech companies and smaller firms. Internal R&D is no longer the primary source, or even an important source, of drug innovation. As a result, analyses that focus on the impacts of pharmaceutical consolidation on internal drug innovation are incomplete and missing the point. Instead, merger analyses should examine whether consolidation increases demand for externally-sourced innovation and, ultimately, strengthens aggregate drug innovation.

Author: Jan Schmidt
Publisher: GRIN Verlag
ISBN: 3656962162
Category : Business & Economics
Languages : en
Pages : 55

View

Book Description
Master's Thesis from the year 2013 in the subject Business economics - Miscellaneous, grade: 8,5 (NL, äquivalent zu 1,2), Utrecht University (Law, Economics and Governance), course: Mergers & Akquisitions, language: English, abstract: The number and volume of pharmaceutical companies’ mergers and acquisitions have reached exorbitant magnitudes in the last decade, with estimations of over 1,300 deals worth US$ 690 billion between 2000 and 2009.1 The biggest transaction, valued at US$ 66.7 billion2, occurred in 2009 when Pfizer bought Wyeth. The sheer dimension of transactions in this sector, being subject to significant public interest, poses questions about the motivations behind these deals, which are mostly believed to be countermeasures for patent expirations, as well as the impact on drug innovation. Even though, the regular object of interest regarding mergers is the shareholder value, in this specific case drug innovation is of particular interest as it does not only influence the future prospects of the pharmaceutical companies but also long term public health. Hence, the objective of this thesis is to discover what the impact of pharmaceutical mergers on R&D intensity and efficiency of the acquiring organization and on the pharmaceutical industry as a whole is.